REVOLUTIONARY ADVANCES PROVIDED BY DIGITAL TWINS FOCUS OF EVENT AT DISCOVERY PARK

Sell-out ‘Two’s Company’ conference led by Pfizer UK, University of Kent, Kent, Surrey and Sussex AHSN

CEO Update|Monday 17 February

Boris Johnson has now confirmed his new Cabinet in a process which started with the surprise departure of Sajid Javid as Chancellor of the Exchequer.

Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed Dr David Morris MD as Chief Medical Officer to lead the Company’s respiratory programmes.

Guest Blog | From open access science to open door laboratories

How unifying departments within academic institutions can increase research efficiency

CEO Update|Monday 10 February

You’ll be aware that the global battle against the coronavirus is well underway and there is important detail for member companies in this blog, about our sector’s response to the outbreak.

Guest Blog|In2scienceUK - an award winning charity looking to change the face of STEM

In 2020 the BIA is supporting the award winning charity In2scienceUK in their mission to diversify the science sector and give those with the fewest opportunities the chance to gain the experience, confidence, skills and networks to support their future career in science.

State of the Market for Directors & Officers Liability Insurance (D&O)

In Gallagher’s state of the market report published in February 2019, we wrote that we did not expect market conditions to improve for the better in 2019. Unfortunately, that prediction has held, and as we enter into Q1 2020, the Directors’ and Officers’ (D&O) insurance market remains a difficult place in which to do business.

BIA response to UK government’s plans for free trade deals and tariff plans

Steve Bates OBE, Chief Executive of the BioIndustry Association said: “For the UK life sciences sector to understand the benefit of any free trade deal we need to see the granular detail of what the UK hopes to achieve. Strengthening Intellectual Property regimes globally would benefit innovative UK life sciences businesses, so it is positive to see the Government recognises the importance of this issue in planning a US FTA.”

CEO Update|Monday 03 February 2020

The UK officially left the E U last Friday. Today we saw greater clarity from both sides on how they plan to approach the upcoming negotiations about the future relationship. This morning’s speech by Boris Johnson, the Written Ministerial Statement and the new European Commission document authorising the opening of negotiations for a new partnership with the UK, together give an idea of where we might be headed and some of the obstacles to reaching agreement.

BIA on Brexit

Despite the rollercoaster political backdrop since the referendum result the UK biotech sector is heading into the new decade and life outside the EU in a very strong position. As the BIA’s recently launched annual finance report showed, 2019 was the third best year recorded and the fifth consecutive year in which more than £1bn was raised. It’s clear that UK biotech companies remain an attractive investment opportunity for global investors.